Tag:

United Kingdom

Latest Headlines

Latest Headlines

Biotech spared in U.K. rejig of VC trusts

The United Kingdom is to change the laws governing startup investment vehicles known as Venture Capital Trusts (VCTs) but has opted against some of the dramatic alterations previously mooted. VCTs will still face new restrictions on the companies to which they can provide private equity cash, though.

Genomics England doles out $12M as sequencing yields early breakthroughs

The 100,000 Genomes Project is up and running in the United Kingdom. And with the population-scale sequencing drive having already made breakthroughs in identifying rare diseases, Genomics England has handed out $12 million to bolster its data analysis capabilities.

U.K. looks to FDA 'breakthrough' status for inspiration in regulatory revamp

The United Kingdom government has established the scope of the hotly anticipated review into the development and reimbursement of drugs. And the independent panel is being tasked with looking beyond the U.K.'s borders for inspiration, with an analysis of what can be learnt from the U.S. FDA's "breakthrough" designation on its to-do list.

U.K. starts on $85M cell manufacturing facility at sensitive time

The U.K. is moving forward with a £55 million ($85 million) cell-manufacturing facility it is supporting in an effort to boost biotech capabilities in the country. It comes at a crucial juncture for the country, which has seen its drug manufacturing shrink to the point that it now imports more pharma products than it exports.

Government attention yet to stop slide in U.K. pharma R&D investment

The United Kingdom government has made the life science industry a focal point of its turnaround strategy, but data that have dripped out over the past few months show companies are spending less and less on developing and manufacturing drugs in the state.

U.K. readies dementia R&D investment fund

Few could fault the United Kingdom for aiming too low. Having seen its CNS R&D chops whittled away by Big Pharma cuts, the U.K. government has decided the best way out of the mire is to take aim at one of the trickiest fields of all with a multimillion-pound dementia R&D investment fund.

Pakistan's new drug pricing policy to cut some costs by one-third

Pakistan's minister in charge of drug pricing confirmed at a news conference a new policy would reduce the costs of some drugs by as much as 30%, but said no changes would become effective before June 30, 2016.

England's price watchdog writes off Celgene's Imnovid in final guidance

The U.K.'s cost-effectiveness gatekeeper is singing an increasingly harsh tune when it comes to greenlighting cancer drugs, and Celgene's Imnovid is the latest med to get a thumbs-down from the watchdog.

U.K. regulators shut down plant making potentially contaminated drug

Regulators in the U.K. have closed down a manufacturing operation there that was making unapproved, unlicensed globulin component macrophage activating factor, a blood product which has the potential to stimulate macrophages to kill cancer cells and stimulate the immune system but is not yet approved for use.

U.K. panel calls for innovation fund to break antibiotic discovery dam

A panel set up by the United Kingdom government to review antimicrobial resistance has called for the creation of a global innovation fund to spur the discovery of new drugs. The idea is to counter years of underinvestment by public and private players in basic to mid-stage scientific research.